Comparative Pharmacology
Head-to-head clinical analysis: IFOSFAMIDE versus URACIL MUSTARD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IFOSFAMIDE versus URACIL MUSTARD.
IFOSFAMIDE vs URACIL MUSTARD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Prodrug activated by cytochrome P450 to cytotoxic metabolites (4-hydroxyifosfamide, acrolein, and ifosforamide mustard) that alkylate DNA by cross-linking guanine bases, inhibiting DNA replication and transcription.
Uracil mustard is a nitrogen mustard alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription, leading to cell death.
1.2 g/m² IV over 2 hours daily for 5 consecutive days every 3 weeks, or 5 g/m² IV as a 24-hour continuous infusion every 3 weeks. Administer with mesna and vigorous hydration.
1 mg orally daily for 3 weeks, then 1 mg daily every 4 weeks, or 0.15 mg/kg orally once weekly.
None Documented
None Documented
Clinical Note
moderateIfosfamide + Digoxin
"Ifosfamide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateUracil mustard + Digoxin
"Uracil mustard may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateIfosfamide + Digitoxin
"Ifosfamide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateUracil mustard + Digitoxin
"Uracil mustard may decrease the cardiotoxic activities of Digitoxin."
Terminal half-life: 4-7 hours for parent drug; active metabolite 4-desulfonate has half-life ~12-15 hours. Clinical context: Prolonged with renal impairment.
Terminal half-life approximately 6–8 hours in patients with normal renal function; may be prolonged with renal impairment
Primarily renal: 50-60% excreted unchanged in urine. Biliary/fecal excretion is minimal (<5%).
Primarily renal (56-80% as unchanged drug and metabolites); minor fecal (10%)
Category D/X
Category C
Alkylating Agent
Alkylating Agent